|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Acute calculous cholecystitis associated with hepatic artery pseudoaneurysm after percutaneous transhepatic gallbladder drainage in a diabetic patient显示文摘Patients with acute calculous cholecystitis are usually undertaken surgery laparoscopic cholecystectomy.However,there are controversies about the decision of operation for patients with high risk factors.Percutaneous transhepatic gallbladder drainage (PTGD) is palliative therapy to alleviate symptoms and physical signs.Since improved clinical outcome has been observed for PTGD,it was recommended as an initial therapeutic option for high risk patients who might need surgery.1 Percutaneous drainage in acute calculous cholecystitis for high risk patients is to be a safe and successful treatment option for patients less eligible for surgery.2 PTGD is relatively safe,but has certain complications.We provided a case report of acute calculous cholecystitis associated with hepatic artery pseudoaneurysm after PTGD in a diabetes mellitus patient.The liver vascular pseudoaneurysms and secondary changes of liver were documented by the imaging examination.The complex interactions among inflammation,bleeding,and diabetes mellitus were involved in this case. | Tian Hu Xia Mingfeng Zhang Shuai Li Jie Liu Ju | 2014 | Chinese Medical Journal2014，，17： | 9 |
| 2 | Engineered trimeric ACE2 binds viral spike protein and locks it in'Thfee-up'conformation to potently inhibit SARS-CoV-2 infection显示文摘Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in a severe global pandemic Following SARS-CoV,SARS-CoV-2 is yet another emerge nt beta-coronavirus threate ning human health.1 However,seventeen years after the SARS pandemic,no targeted vaccines or therapeutics have been approved for SARS,while some of them might have held promise for treating COVID-19.Many neutralizing antibodies against SARS-CoV-2 are currently being developed.However,RNA viruses are known to have high mutation rates. | Liang Guo Wenwen Bi Xinling Wang Wei Xu Renhong Yan Yuanyuan Zhang Kai Zhao Yaning Li Mingfeng Zhang Xia Cai Shibo Jiang Youhua Xie Qiang Zhou Lu Lu Bobo Dang | 2021 | Cell Research2021，31，1： | 5 |
| 3 | Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial显示文摘Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment.We conducted a randomized,controlled,open-label multicenter trial among COVID-19 patients.The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone.The cure rate,changes of oxygen saturation and interference,and inflammation biomarkers were observed.Thirty-three patients were randomized to the tocilizumab group,and 32 patients to the control group.The cure rate in the tocilizumab group was higher than that in the control group,but the difference was not statistically significant(94.12%vs.87.10%,rate difference 95%CI−7.19%–21.23%,P=0.4133).The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12(P=0.0359).In moderate disease patients with bilateral pulmonary lesions,the hypoxia ameliorated earlier after tocilizumab treatment,and less patients(1/12,8.33%)needed an increase of inhaled oxygen concentration compared with the controls(4/6,66.67%;rate difference 95%CI−99.17%to−17.50%,P=0.0217).No severe adverse events occurred.More mild temporary adverse events were recorded in tocilizumab recipients(20/34,58.82%)than the controls(4/31,12.90%).Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes negative.For patients with bilateral pulmonary lesions and elevated IL-6 levels,tocilizumab could be recommended to improve outcome. | Dongsheng Wang Binqing Fu Zhen Peng Dongliang Yang Mingfeng Han Min Li Yun Yang Tianjun Yang Liangye Sun Wei Li Wei Shi Xin Yao Yan Ma Fei Xu Xiaojing Wang Jun Chen Daqing Xia Yubei Sun Lin Dong Jumei Wang Xiaoyu Zhu Min Zhang Yonggang Zhou Aijun Pan Xiaowen Hu Xiaodong Mei Haiming Wei Xiaoling Xu | 2021 | Frontiers of Medicine2021，15，3： | 2 |
| 4 | Cold water stress attenuates dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice显示文摘在现在的学习,我们在导致的 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP ) 在 dopaminergic 神经原上测试了冷水应力(CWS ) 的效果 Parkinson 是疾病(PD ) 老鼠模型,并且发现那个 CWS 预告的处理得到了更少的 MPTP neurotoxicity。理解位于这现象下面的分子的机制,我们在试验性的鼠标的 striatum 检测了热吃惊蛋白质 70 的表达式(Hsp70 ) ,并且发现那个 CWS 预告的处理能显著地在对待 MPTP 的鼠标增加 striatal Hsp70。与 Hsp70 的正式就职同时,而且, striatal -synuclein 的导致 MPTP 的增加在 CWS +对待 MPTP 的老鼠被禁止。CWS 预告的处理显著地也在 striatum 禁止了 anti-apoptotic 分子 Bcl-2 表示的减小并且在对待 MPTP 的老鼠的 substantia nigra 提高了 Bcl-2 抄写。一起拿,这些数据显示 Hsp70 可能是为对导致 MPTP 的 dopaminergic 毒性的 CWS 的 neuroprotective 效果的重要中介。 | Mingfeng Xia Minjuan Bian Qian Yu Jie Liu Yufang Huang Xueting Jin Shiduo Lu Mei Yu Fang Huang | 2011 | Acta Biochimica et Biophysica Sinica2011，43，6： | 1 |
| 5 | Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy显示文摘Immune checkpoint inhibitors(ICI)targeting PD-1/PD-L1 have been approved for the treatment of a variety of cancers.However,the efficacy of antibody-based ICIs could be further improved by mitigating anti-drug antibodies,proteolytic cleavage,and on-target off-tumor toxicity.One strategy for accomplishing this is through the use of extracellular vesicles(EVs),cell derived submicron vesicles with many unique properties.We constructed an engineered MDA-MB-231 cell line for harvesting EVs.This was accomplished by overexpressing a high-affinity variant human PD-1 protein(havPD-1),while simultaneously knocking out intrinsic PD-L1 and beta-2 microglobulin.The engineered havPD-1 EVs reduced PD-L1 overexpressing cancer cell proliferation and induced cellular apoptosis.Moreover,the EVs were shown to efficiently block PD-L1 mediated T cell suppression.Meanwhile antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity were not observed.The havPD-1 EVs treatment resulted in robust anti-tumor activity in both preventative co-implantation and therapeutic xenograft tumor models reconstituted with human T cells.The efficacy of the havPD-1 EVs was shown to be comparable to clinical anti-PD1 monoclonal antibodies.Additionally,loading the havPD-1 EVs with a potent PARP inhibitor was shown to further augment treatment efficacy.In brief,the engineered universal EVs harboring havPD-1 proteins can be used for cancer concurrent immunotherapy and chemotherapy. | Yundi Chen Lixue Wang Mingfeng Zheng Chuandong Zhu Guosheng Wang Yiqiu Xia Ethan J.Blumenthal Wenjun Mao Yuan Wan | 2022 | Bioactive Materials2022，7，3： | 1 |
| 6 | Antisense oligonucleotide technology can be used to investigate a circular but not linear RNA-mediated function for its encoded gene locus显示文摘As a class of powerful molecular tool,antisense oligonucleotides(ASOs)are not only broadly used in protein and RNA biology,but also a highly selective therapeutic strategy for many diseases.Although the concept that ASO reagents only reduce expression of the targeted gene in a post-transcriptional manner has long been established,the effect and mechanism of ASO reagents on RNA polymerase II(Pol II)transcription are largely unknown.This raised question is particularly important for the appropriate use of ASOs and the valid interpretation of ASO-mediated experiments.In this study,our results show that linear RNA ASO attenuates transcription of nascent transcripts by inducing premature transcription termination which is combinatorially controlled by Integrator,exosome,and Rat1 in Drosophila.However,circular RNA(circRNA)ASO transfection does not affect transcription activity of the encoded gene.These data suggest that the ASO technique can be applied to study a circRNA-mediated but not linear RNA-mediated function for its encoded gene locus. | Zhenxing Song Ruirui Jia Mingfeng Tang Fei Xia Haiyang Xu Zhengguo Li Chuan Huang | 2021 | Science China(Life Sciences)2021，64，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员